Five of the world’s biggest drugs companies have agreed to slash the price of
their anti-HIV drugs in developing countries by 85 per cent following sustained
pressure from health agencies, Third World governments and patient groups
(Â鶹´«Ã½, 29 April, p 14).
One of the companies, Glaxo Wellcome, is
cutting the price of triple drug therapy from $16 to $2 a day. But
pressure groups have warned that even at these prices, poverty and a lack of
health infrastructure in poor countries will mean the benefits are limited.
To continue reading, today with our introductory offers
Advertisement
More from Â鶹´«Ã½
Explore the latest news, articles and features
Popular articles
Trending Â鶹´«Ã½ articles
1
Are Neanderthals descendants of modern humans?
2
Collapse of key ocean current may release billions of tonnes of carbon
3
Exclusive report: Inside Chernobyl, 40 years after nuclear disaster
4
Beef is making a comeback – does it fit into a healthy diet?
5
Why is it so hard to change your mind?
6
The biggest threat to Chernobyl is no longer radiation
7
How autoimmune conditions can unexpectedly drive mental illness
8
Electric vehicle owners could earn thousands by supporting power grid
9
Surprising male G-spot found in most detailed study of the penis yet
10
The rise, the fall and the rebound of cyclic cosmology
